|
Smith & Nephew PLC shares climbed on Wednesday as it said it made a good start to 2025 as revenue increased. The Watford, England-based medical technology company said first-quarter revenue rose 1.6% to $1.41 billion from $1.39 billion, with underlying revenue growth of 3.1%. Shares in Smith & Nephew were up 7.5% to 1,070.82 pence in London on Wednesday morning. The company said growth was driven by operational improvements and recent product launches, and includes continued headwinds from China and one less trading day compared to the prior year. Smith & Nephew said headwinds from China ‘remain an offsetting factor’ but it believes it has passed their peak impact. The company left its 2025 guidance unchanged, with expected revenue growth of 5.4%, and 5.0% underlying growth. Smith & Nephew said the unchanged outlook includes an expected net impact of between $15 million and $20 million from tariffs. ‘Whilst uncertainties exist around the imposition of tariffs, we remain confident in our outlook for another year of strong revenue growth and a significant step-up in trading profit margin,’ said Chief Executive Officer Deepak Nath. Smith & Nephew said Orthopaedics revenue grew 1.8% in the first quarter, with sustained improved performance in US Hip and Knee Implants. Sports Medicine and ENT revenue was up 0.9% with growth in Sports Medicine Joint Repair. Revenue in Advanced Wound Management increased 2.0%. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
